BP Meds May Not Eliminate CVD Risk The new KDIGO guideline recommendation to target a systolic blood pressure of less than 120mmHg in many patients with nondialysis CKD is lower than the 2012 ...

KDIGO released new guidelines on chronic kidney disease-mineral and bone disorder for nephrologists and primary care physicians, many of whom care for patients with chronic kidney disease themselves.

Kidney Disease: Improving Global Outcomes has announced the release of its 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.The executive summary co ...

In the KDIGO announcement of the publication of the 2024 CKD guideline, Adeera Levin MD, one of the Guideline Committee Co-Chairs said, “Recent advancements in GFR evaluation, risk prediction ...

Group summarizes new guidelines for treating patients with diabetes and chronic kidney disease 2022 update provides important clarifications to 2020 guidelines Guideline: https://www.acpjournals ...

Natera, Inc., a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, which was recently ...

So with that as a foundation, it also touches upon the changes in the guidelines. Now the KDIGO [Kidney Disease Improving Global Outcomes] guidelines [have been around] since 2003.

Foti KE, Wang D, Chang AR, et al. Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States. Kidney Int . 99(3):686-695. doi:10. ...

The KDIGO guideline, specifically in Practice Points 1.1.4.1 and 1.1.4.2, states that genetic tests should be used, among other factors, to establish cause for CKD, and that genetic testing can ...

Guidelines highlight the importance of risk prediction and personalized treatment to reduce riskLONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) ...

LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the ...